Sertraline updated on 07-01-2025

Hypospadias

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7468
R22187		 Anderson, 2020 Hypospadias, 2nd or 3rd degree 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 1.35 [0.89;2.06] -/-   0/- - -
ref
S6008
R15431		 Furu, 2015 Hypospadias 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 0.81 [0.48;1.38] 15/7,245   4,526/2,266,875 4,541 7,245
ref
S7352
R21532		 Wemakor, 2015 Hypospadias 1st trimester case control unexposed (general population or NOS) Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 0.80 [0.18;3.53] C 2/16   3,039/20,108 3,041 16
ref
S18287
R76959		 Reis (Controls exposed to TCA), 2010 Hypospadias early pregnancy population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 0.45 [0.17;1.16] C
excluded (control group) 		8/3,297   9/1,662 17 3,297
ref
S18288
R76963		 Reis (Controls unexposed, NOS), 2010 Hypospadias early pregnancy population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 0.89 [0.38;1.75] 8/3,297   -/1,062,190 - 3,297
ref
S6159
R16159		 Louik, 2007 Hypospadias 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 1.20 [0.40;4.20] 3/49   494/6,308 497 49
ref
Total 5 studies 1.07 [0.80;1.42] 8,079 10,607
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Anderson, 2020Anderson, 2020 1.35[0.89; 2.06]--47%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: lowROB mesure: unclearROB reporting: moderate Furu, 2015Furu, 2015 0.81[0.48; 1.38]4,5417,24529%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Wemakor, 2015Wemakor, 2015 0.80[0.18; 3.53]3,041164%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Reis (Controls unexposed, NOS), 2010Reis, 2010 1 0.89[0.38; 1.75]-3,29714%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: lowROB mesure: unclearROB reporting: moderate Louik, 2007Louik, 2007 1.20[0.40; 4.20]497496%ROB confusion: moderateROB selection: criticalROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Total (5 studies) I2 = 0% 1.07[0.80; 1.42]8,07910,6070.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.84[0.54; 1.29]4,54110,5420%NAFuru, 2015 Reis (Controls unexposed, NOS), 2010 2 case control studiescase control studies 1.29[0.88; 1.89]3,538650%NAAnderson, 2020 Wemakor, 2015 Louik, 2007 3 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.07[0.80; 1.42]8,07910,6070%NAAnderson, 2020 Furu, 2015 Wemakor, 2015 Reis (Controls unexposed, NOS), 2010 Louik, 2007 5 Tags Adjustment   - No  - No 0.80[0.18; 3.53]3,04116 -NAWemakor, 2015 1   - Yes  - Yes 1.08[0.80; 1.44]5,03810,5910%NAAnderson, 2020 Furu, 2015 Reis (Controls unexposed, NOS), 2010 Louik, 2007 4 Monotherapy   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 1.07[0.74; 1.55]7,5827,26116%NAAnderson, 2020 Furu, 2015 Wemakor, 2015 3   - substance alone among the specific ...  - substance alone among the specific class of antidep (SSRI, SNRI, ...) 0.97[0.51; 1.85]4973,3460%NAReis (Controls unexposed, NOS), 2010 Louik, 2007 2 All studiesAll studies 1.07[0.80; 1.42]8,07910,6070%NAAnderson, 2020 Furu, 2015 Wemakor, 2015 Reis (Controls unexposed, NOS), 2010 Louik, 2007 50.25.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-1.81.80.9070.000Anderson, 2020Furu, 2015Wemakor, 2015Reis (Controls unexposed, NOS), 2010Louik, 2007

Asymetry test p-value = 0.5327 (by Egger's regression)

slope=0.2635 (0.3108); intercept=-0.6679 (0.9501); t=0.7030; p=0.5327

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 18287

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.07[0.80; 1.42]8,07910,6070%NAAnderson, 2020 Furu, 2015 Wemakor, 2015 Reis (Controls unexposed, NOS), 2010 Louik, 2007 5 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale0.45[0.17; 1.16]173,297 -NAReis (Controls exposed to TCA), 2010 10.510.01.0